(HEALTH) – Mundipharma, an affiliate of OxyContin maker Purdue Pharma, now has an overdose antidote for sale. Purdue Pharma is widely blamed for the overdose epidemic.
It appears they are now cashing in on both sides of the situation.
Dr. Andrew Kolodny testified against the company in court claiming that the company is in the business of selling medicine that caused and causes addiction and overdoses and now they are selling the medicine that treats those same issues. “That’s pretty clever, isn’t it?” he said.
The Sackler family, who owns the company, is among the richest in the world, in part, because of OxyContin and other medications. Globally, the company is working towards the domination of the market for opioid overdose treatment. Mundipharma has expanded across the globe.
The antidote, a naloxone nasal spray branded Nyxoid, is now available in Europe, Australia and Europe. They are defending the product as a badly needed tool in the fight against overdoses. Heroin is a leading cause of overdose death in European countries and a nasal spray is an important option.
Injectable naloxone has been available for a long time. The product is cheap and available in a generic brand. Nyxoid is a first for many countries where it comes packaged and ready to use as is. It is considered an easier way for those to intervene in an overdose. Nyxoid is more expensive than injectable naloxone at more than $50 a dose in some countries. Narcan is available in North America for years and is cheaper.